FDA Says Patient Pleas No Substitute for Scientific Evidence

Posted by Sarah Showard | Mar 24, 2016 | 0 Comments

FDA Says Patient Pleas No Substitute for Scientific Evidence

Despite a 2012 directive from Congress to better include patients in the development of treatments for disease, the Food and Drug Administration (FDA) says that the key to a drug's approval is still scientific evidence.

A recent Bloomberg report noted that a drug to treat Duchenne's muscular dystrophy, Kyndrisa from BioMarin Pharmaceutical, failed to gain FDA approval in January 2016 despite pleas from patients because the FDA said it failed to provide clear scientific evidence that it helped patients. Duchenne's is a rare form of muscular dystrophy that affects 1 in 3,600 boys.

Another Duchenne's drug -- Translarna from PTC Therapeutics -- was also rejected by the FDA for failure to show that patients on the drug fared better than those who were given a placebo.

According to the Bloomberg report, drug companies sometimes skip randomized clinical trials for drugs to treat rare or particularly deadly diseases. However, it is these trials that the FDA depends on to approve or reject a drug.

“I would prefer seeing randomization very, very early” in the drug testing process, FDA's Center for Drug Evaluation and Research director Janet Woodcock told Bloomberg. “Even if there's a small, tiny effect, it may be meaningful to that patient population. If they can show there is definitely a small effect in a terrible disease, we will approve that drug.”

There have been drugs that have been approved in part due to patient advocacy groups. Addyi, a drug used to treat low female libido, was rejected twice before it was approved last year following a patient advocacy campaign that was funded in part by the drug's manufacturer, Sprout Pharmaceuticals.

The FDA is currently working with patient organizations on identifying key issues in drug development for muscular dystrophy. The Parent Project Muscular Dystrophy organization has suggested that the agency use different measures to determine a drug's benefit.

Showard Law Firm focuses on helping people who have been injured in accidents or have been the victim of faulty medical products. Contact us to schedule your free consultation with our experienced personal injury legal team for the compassionate representation you deserve.

About the Author

Sarah Showard

Sarah Showard graduated from the University of Maryland in 1985, Magna Cum Laude with a Bachelor of Arts in English-Linguistics and a Certification in Women's Studies. She then graduated from New York University School of Law in 1988. Sarah began practice initially as an insurance defense attorney, and has been representing plaintiffs since 1990. Sarah has a son, Benjamin, who recently graduated from The Gregory School and will attend ASU in the fall, with future plans to attend law school and eventually join Showard Law Firm. In her spare time Sarah enjoys horseback riding and spending time in Sonoita with her husband Peter.


There are no comments for this post. Be the first and Add your Comment below.

Leave a Comment

Showard Law Firm-Tucson's Local Law Firm for defective drug & medical device claims.

Showard law firm group photo compressor

Showard Law Firm is dedicated to compassionate representation for our clients who have been injured by defective products, dangerous drugs or the negligence of any individual or company. We are experienced in litigation and ready to ensure you receive the maximum possible settlement for your injuries, medical bills, mental anguish and other losses.

Showard Law Firm celebrates 10 years

10th anniversary showard

2016 marked the 10th anniversary of Showard Law Firm. After 18 years of practice, and a prior ten-year partnership, Sarah Showard and her longtime assistant, Maria De La Rosa, opened the doors of Showard Law Firm in October 2006. Sarah and everyone at Showard Law Firm is proud to serve Southern Arizona as the local law firm for defective drug and medical device claims and personal injury.